Nicole Eiseler, MD
Medical Oncology · Miami, FLNPI 1144454257
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Deciphera Pharmaceuticals Inc. accounts for 69.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $4,934 and has fallen 98.2% since, to $90 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 30 payments — averaging $325.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$7K
- Springworks Therapeutics, Inc.$2K
- AstraZeneca$183
- Rigel Pharmaceuticals, Inc.$103
- Merck$99
- Aadi Bioscience, Inc.$55
- plus $90 from 4 others
Across 4 payments — averaging $35,787 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$123K
- Merck$20K
What the payments were for
- Consulting fees$5,61057%
- Speaking & faculty fees$1,66517%
- Travel & lodging$1,51916%
- Food & beverage$97610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 17 | $6,826 |
| Springworks Therapeutics, Inc. | 3 | $2,413 |
| AstraZeneca(2 entities) | 3 | $183 |
| Rigel Pharmaceuticals, Inc. | 1 | $103 |
| Merck | 1 | $99 |
| Aadi Bioscience, Inc. | 1 | $55 |
| Johnson & Johnson | 1 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QINLOCK$4,038
- OGSIVEO$2,385
- VIMSELTINIB$2,330
- ULTOMIRIS$127
- Tavalisse$103
How this compares
$9,770 in reported general payments places this provider in the 50th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 13 | $100 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Miami
- Neil LoveMiami$5.6M
- Sarbajit MukherjeeMiami$232K
- Bruna Pellini FerreiraMiami$158K
- Coral OlazagastiMiami$134K
- Jonathan TrentMiami$102K
- Gilberto LopesMiami$99K
- Craig MoskowitzMiami$94K
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.